Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factors and comparison with supradiaphragmatic disease

Haematologica

Volumn 91, Issue 1, 2006, Pages 32-39

  Vassilakopoulos, Theodoras P ^a   Angelopoulou, Maria K ^a   Siakantaris, Marina P ^a   Konstantinou, Nikos ^b   Symeonidis, Argyrios ^c   Karmiris, Themistoklis ^d   Repoussis, Panayiotis ^e   Roussou, Paraskevi ^a   Dimopoulos, Athanassios Meletios ^a   Kokoris, Styliani I ^a   Dimitriadou, Evangelia M ^a   Kyrtsonis, Marie Christine ^a   Dimopoulou, Maria N ^a   Tsatalas, Constantinos ^f   Kokkinis, Garyfallia ^g   Vrakidou, Effimia ^h   Grigoraki, Vassiliki ⁱ   Poziopoulos, Christos ^j   Stamatellou, Marina ^k   Liapis, Dimitra ^l   Georgiou, George ^a   Panayiotidis, Panayiotis ^a   Pangalis, Gerassimos A ^a   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

^e Peripheral General Anticancer Hospital Metaxa   (Greece)

^f DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^g SISMANOGLIO HOSPITAL   (Greece)

^h HYGEIA HOSPITAL   (Greece)

ⁱ KAT HOSPITAL   (Greece)

^j 401 Army Hospital   (Greece)

^k O Aghios Savas Hospital   (Greece)

^l Venizelion General Hospital   (Greece)

more..

Author keywords

Chemotherapy; Hodgkin's lymphoma; Infradiaphragmatic; Prognostic factors

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PROGNOSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

HODGKIN DISEASE; HUMANS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 32544460618     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Vassilakopoulos TP, Angelopoulou MK, Kontopidou FN, Siakantaris MP, Barbounis A, Hadjioannou M, et al. Pure infradiaphragmatic Hodgkin's disease. Analysis of twenty five cases and review of the literature. Haema 1999; 2:90-100.
2. Krikorian JG, Portlock CS, Mauch PM. Hodgkin's disease presenting below the diaphragm: a review. J Clin Oncol 1986;4:1551-62.
3. Krikorian JG, Portlock CS, Rosenberg SA, Kaplan HS. Hodgkin's disease, stages I and II occurring below the diaphragm. Cancer 1979;43:1866-71.
4. Pene F, Henry-Amar M, Le Bourgeois JP, Hayat M, Gerard-Marchant R, Laugier A, et al. A study of relapse and course of 153 cases of Hodgkin's disease (clinical stages I and II) treated at the Institute Gustave-Roussy from 1963 to 1970 with radiotherapy alone or with adjuvant monochemotherapy. Cancer 1980;46:2131-41.
5. Barrett A, Gregor A, McElwain TJ, Peckham MJ. Infradiaphragmatic presentation of Hodgkin's disease. Clin Radiol 1981;32:221-4.
6. Cionini L, Magrini S, Mungai V, Biti GP, Ponticelli P. Stage I and II Hodgkin's disease presenting in infradiaphragmatic nodes. Tumori 1982;68:519-25.
7. Mauch P, Greenberg H, Lewin A, Cassady R, Weichselbaum R, Hellman S. Prognostic factors in patients with subdiaphragmatic Hodgkin's disease. Hematol Oncol 1983;1:205-14.
8. Dorreen MS, Wrigley PFM, Jones AE, Shand WS, Stansfeld AG, Lister TA. The management of localized, infradiaphragmatic Hodgkin's disease: experience of a rare clinical presentation at St Bartholomew's Hospital. Hematol Oncol 1984;2:349-57.
9. Lanzillo JH, Moylan DJ, Mohiuddin M, Kramer S. Radiotherapy of stage I and II Hodgkin's disease with inguinal presentation. Radiology 1985;154:213-5.
10. Leibenhaut MH, Hoppe RT, Varghese A, Rosenberg SA. Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients. J Clin Oncol 1987;5:1050-5.
11. Specht L, Nissen NI. Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination. Eur J Haematol 1988;40:396-402.
12. Frassica DA, Schomberg PJ, Banks PM, Colgan JP, Ilstrup DM, Earle JD. Management of subdiaphragmatic early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989;16:1459-63.
13. Givens SS, Fuller LM, Hagemeister FB, Gehan EA. Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine and prednisone. Cancer 1990; 66:69-74.
14. Villamor N, Reverter JC, Marti JM, Montserrat E, Rozman C. Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease. Eur J Haematol 1991;46:38-41.
15. Liew KH, Ding JC, Cruickshank D, quong GG, Wolf MM, Cooper IA. Infradiaphragmatic Hodgkin's disease, long term follow-up of a rare presentation. Aust NZ J Med 1991;21:16-21.
16. Mai DHW, Peschel RE, Portlock C, Knowlton A, Farber L. Stage I and II subdiaphragmatic Hodgkin's disease. Cancer 1991;68:1476-81.
17. Roos DE, O'Brien P, Wright J, Willson K. Treatment of subdiaphragmatic Hodgkin's disease: is radiotnerapy alone appropriate only for inguinofemoral presentations? Int J Radiat Oncol Biol Phys 1994;28:683-91.
18. Barton M, Boyages J, Crennan E, Davis S, Fisher RJ, Hook C, et al. Radiotherapy for early infradiaphragmatic Hodgkin's disease: The Australasian experience. Radiother Oncol 1996;39: 1-7.
19. Ifrah N, Hunault M, Jais JP, Moreau P, Desablens B, Casassus P, et al. Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. Leuk Lymphoma 1996;21:79-84.
20. Enrici RM, Osti MF, Anselmo AP, Banelli E, Cartoni C, Sbarbati S, et al. Hodgkin's disease stage I and II with exclusive subdiaphragmatic presentation. The experience of the Departments of Radiation, Oncology and Hematology, University "La Sapienza" of Rome. Tumori 1996;82:48-52.
21. Iannitto E, Accurso V, Federico M, Vallisa D, Pieresca C, Gravina SF, et al. Hodgkin's disease presenting below the diaphragm. The experience of the Gruppo Italiano Studio Linfomi (GISL). Haematologica 1997;82:676-82.
22. Kalkner KM, Enblad G, Gustavsson EG, Starkhammar H, Branehog H, Lenner P, et al. Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Eur J Haematol 1997;59:31-7.
23. Illes A, Vadasz G, Banyai A, Szegedi G. Infradiaphragmatic Hodgkin's disease. Haematologia 1997;28:117-22.
24. Liao Z, Ha CS, Fuller LM, Hagemeister FB, Cabanillas F, Tucker SL, et al. Subdiaphragmatic stage I and II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 1998;41:1047-56.
25. Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl , et al. Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma 2005;46:1715-20.
26. Cutuli B, Petit T, Hoffstetter S, Veiten M, Dufour P, Giron C, et al. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects. Oncol Rep 1998;5:1513-8.
27. Hull MC, Mendenhall NP, Colgan ME: Subdiaphragmatic Hodgkin's disease: the University of Florida experience. Int J Radiat Oncol Biol Phys 2002;52: 161-6.
28. Cordoba S, Romero J, De la Torre A, Valcarcel F, Magallon R, Regueiro CA, et al. Early stage infradiaphragmatic Hodgkin's disease: results of radiotherapy and review of the literature. Radiother Oncol 2003;67:259-63.
29. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, et al. Combination chemotherapy plus low dose involved field radiation for early clinical stage Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2004;59:765-81.
30. Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJV, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258-72.
31. Noordijk EM, Carde P, Mandard AM, Mellink WA, Monconduit M, Eghbali H, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann Oncol 1994; 5 Suppl 2:S107-S112.
32. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
33. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, et al. Bcl-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935-41.
34. Diehl V, Klimm B, Re D. Hodgkin lymphoma: a curable disease: what comes next? Eur J Haematol 2005; 75 Suppl 66:6-13.
35. Bonadonna G, Zucali R, Morfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.
36. Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kontopidou FN, Boussiotis VA, Papavassiliou C, et al. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma 2000;37:131-43.
37. Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997;15:1638-45.
38. Eghbali H, Raemaekers J, Carde P, EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol 2005;75 Suppl 66:135-40.
39. Carbone PP, Kaplan HS, Musshof K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging. Cancer Res 1971;31:1860-1.
40. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.
41. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:185-206.
42. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc 1972;135(A):185-207.
43. Cox DR. Regression models and life tables (with Discussion). J R Stat Soc B 1972;34:187-220.
44. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kokoris SI, Pangalis GA. Hodgkin's lymphoma: treatment and prognosis. Haema 2004;7 Suppl 1:53-63.
45. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
46. 2microglobulin in patients with Hodgkin's lymphoma. Haematologica 2002;87: 701-8.
47. Meyer R, Gospodarowicz MK, Connors J, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23 4634-42.
48. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) followed by radiation therapy (RT) vs. ABVD alone for stages I, II and IIIA non bulky Hodgkin's disease Blood 2004;104:3483-9.
49. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol, 2001;67:279-88.
50. Franklin J, Paulus U, Lieberz D, Breuer K, Tesch H and Diehl V. Is the International Prognostic Score for advanced stage Hodgkin's disease applicable in early stage patients? Ann Oncol 2000;11:617-23.
51. Gisselbrecht C, Mounier N, Andre N, Casanovas O, Reman O, Sebban C, et al. How to define intermediate stage in Hodgkin's lymphomai Eur J Haematol 2005;75 Suppl 66:111-4.